DelveInsight’s Beta-Thalassemia Market report offers a holistic picture of the market landscape of the Beta Thalassemia key companies, emerging pipeline therapies, Beta-Thalassemia market share occupied by individual therapies, current and forecasted Beta-thal market share in the 6MM (the US, and EU5 (the UK, Germany, France, Italy, and Spain) for the study period.
The report highlights the drivers and constraints shaping the present Beta-Thalassemia Market along with the unmet medical needs that offer opportunities to the key players to explore the underlying potential of the market.
Some of the key highlights from the Beta-Thalassemia Market Report:
Get more comprehensive insights into how Beta-Thalassemia epidemiological trends are impacting current and forecasted Beta-Thalassemia market @ Beta-Thalassemia Epidemiology Analysis and Forecast
Beta-Thalassemia Marketed Therapies
Do you want to know how much market share the marketed therapies are going to capture by 2030? Contact @ Beta-Thalassemia Marketed Therapies and Treatment Approaches and get a comprehensive understanding of the Beta-Thalassemia therapeutic outlook
Beta Thalassemia is a genetic disorder which is inherited in an autosomal, recessive fashion. The clinical manifestations seen in patients are severe anaemia, abnormal haemoglobin and buildup of iron in the body. Being a genetic disorder, there is no specific treatment for Beta Thalassemia and the treatment regimen mainly focus on delaying progression of the disease and relieving the symptoms.
Novartis developed Exjade (Deferasirox), which is an oral iron chelator approved by the US FDA in 2005. It is a member of a new class of tridentate iron chelators, the N-substituted bis-hydroxyphenyl-triazoles. Metabolism and elimination of deferasirox are primarily by glucuronidation followed by hepatobiliary excretion into the faeces. Approved in more than 70 countries including the US and Europe, Exjade is the first once-daily oral iron chelator approved for use in patients with chronic transfusional iron overload who have a wide range of underlying anaemias.
Visit to know more about the indication, treatment algorithms in different geographies and patient journey contact to receive sample @ Beta-Thalassemia Signs, Symptoms, Diagnosis and Treatment
Some of the key companies working on Beta-Thalassemia are:
The launch of the emerging therapies is expected to significantly impact the Beta-Thalassemia treatment scenario in the upcoming years:-
Some of Beta-Thalassemia Drugs Covered:
Know more about the collaborations, tie-ups, and therapies launch @ Beta-Thalassemia Pipeline Therapies and Forecast
Table of Contents:
1
Key Insights
2
Executive Summary of Beta-thalassemia
3
SWOT Analysis for Beta-Thalassemia
4
Beta-Thalassemia Market Overview at a Glance
5
Disease Background and Overview
6
Beta-Thalassemia Epidemiology and Patient Population
7
Country-Wise Beta-Thalassemia Epidemiology
8
Beta-Thalassemia Treatment and Management
9
Case Study
10
Beta-Thalassemia Market Unmet Needs
11
Beta-Thalassemia Marketed Products
12
Beta-Thalassemia Emerging Therapies
13
Beta-Thalassemia Promising Candidates
14
Beta-Thalassemia Therapies in the News
15
Beta-Thalassemia Discontinued Therapies
16
Beta-Thalassemia: Six Major Market Analysis
17
Beta-Thalassemia Market Outlook by Country
18
Beta-Thalassemia Market Access and Reimbursement Landscape
19
Beta-Thalassemia Market Drivers
20
Beta-Thalassemia Market Barriers
21
Appendix
22
DelveInsight Capabilities
23
Disclaimer
24
About DelveInsight
Get in touch with our Business Executive @ Beta-Thalassemia Market Outlook in the Next Decade
DelveInsght’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/beta-thalassemia-market-forecast